AIET is a treatment method in which some immune cells are taken out of a patient's body which are cultured and processed to be activated or to acquire additional functions until their resistance to cancer is strengthened, then the cells are put back in the body. The cells, antibodies, and organs of the immune system work to protect and defend the body against not only tumor cells but also foreign invaders, such as bacteria or viruses. Researchers have found that the thus activated immune system might also be able to determine the difference between healthy cells and cancer cells to eliminate the cancer cells from the body.

Upon encountering a tumor cell, the activated NK cell attaches to the membrane of the cancer cell and injects toxic granules that quickly dissolve the target cell. In less than five minutes, the cancer cell would be dead and the NK cell moves on to its next target. A single NK cell can destroy up to 27 cancer cells before it dies. At present our protocol is based on reported clinical experiences from Japan and other developed nations, well accepted by the scientific community. Peripheral blood of the cancer patients (during remission in patients who undergo chemotherapy) is drawn and by proven methods, the peripheral blood mononuclear cells are separated. These cells are expanded in vitro during which they expand to 25-30 fold. Our processing technology specifically expands lymphocytes and NK cells to a significantly greater extent taking around 2-3 weeks.

After expansion, the activated lymphocytes and NK cells are injected into the patient’s body wherein these cells act against the cancer cells effectively and also repopulate the patient’s peripheral blood cells thereby recharging the immune system. Despite numerous advances in medicine, cancer remains a major health problem. It is the second leading cause of death in the world yet much is still not known about its mechanisms of establishment and definitive modalities of complete cure. Globally it is estimated that there are 7.6 million new cancer cases, of which 52% occur in developing countries every year. The magnitude of the problem of cancer in Malaysia in terms of sheer number is most alarming. The estimated new cases of cancer patients in Malaysia per year are nearly 40000. The crude incidence of cancer in India is approximately 100 per 100,000 population. The Cancer in women in the Indian Sub-continent constitutes more than 50% of the total cancer. Recent epidemiological studies done at National Cancer Registry programme in India report that Cancer burden in the country is 2.5 to 3 million and estimated number of new cases diagnosed every year found to be 700,000 - 900,000.

Although the common treatment modalities such as surgery and/or chemo and radiotherapies have played major roles in bringing down the mortality and morbidity to a significant extent, complete cure is still uncertain and the prognosis varies depending upon the stage and the type of the disease. Even when patients experience tumor regression immediately after therapy, recurrence or metastasis (spreading to other parts of the body) can occur later.

• Back • Next •